Month: October 2014

Eyewire Today | New Study Forecasts Number of Diabetic Eye Disease Cases to Reach Nearly 11…

Diabetic retinopathy continues to increase in our population… Eyewire Today | New Study Forecasts Number of Diabetic Eye Disease Cases to Reach Nearly 11… New Study Forecasts Number of Diabetic Eye Disease Cases to Reach Nearly 11 Million by 2032 Return to main website.

Ohr Pharmaceutical Announces Squalamine Eye Drop (OHR-102) Clinical Data Presentations at the…

Dr. Ciulla presented at The American Academy of Ophthalmology recently… Ohr Pharmaceutical Announces Squalamine Eye Drop (OHR-102) Clinical Data Presentations at the… NEW YORK, Oct. 7, 2014 (GLOBE NEWSWIRE) — Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, announced today that additional positive […]

FDA clears Iluvien for DME


A long-acting steroid implant will soon be available for diabetic macular edema…

FDA clears Iluvien for DME

Following resolution of safety concerns, the U.S. FDA has approved Iluvien for diabetic macular edema.


Return to main website.

FDA approves Eylea for BRVO

Another treatment is available for macular edema related to branch retinal vein occlusion… FDA approves Eylea for BRVO Regeneron Pharmaceuticals, Inc., announced that the FDA has approved Eylea (aflibercept) for macular edema following branch retinal vein occlusion. Return to main website.